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Abstract
Background: Multiple sclerosis is an acquired demyelinating disease of the cen-
tral nervous system. It is the second most common cause of disability in adults
in United States after head trauma. Discussion: The etiology of MS is probably
multifactorial, related to genetic, environmental, and several other factors. The
pathogenesis is not fully understood but is believed to involve T-cell-mediated
inflammation directed against myelin and other related proteins with a possible
role for B cells. The McDonald criteria have been proposed and revised over
the years to guide the diagnosis of MS and are based on clinical presentation
and magnetic resonance imaging (MRI) of the brain and spinal cord to estab-
lish dissemination in time and space. The treatment of MS includes disease
modification with immunomodulator drugs and symptom management to
address the specific symptoms such as fatigue, spasticity, and pain. Conclusion:
An update on etiology, pathogenesis, diagnosis, and immunomodulatory treat-
ment of MS is presented.
Introduction
Multiple sclerosis is an autoimmune inflammatory disorder
of CNS of unknown etiology, characterized by demyelina-
tion and variable degrees of axonal loss. The disease affects
mostly young women (between ages 20 and 40 years) and is
one of leading causes of disability in young adults in United
States (Orton et al. 2006; Kister et al. 2013). Its prevalence
in the United States is about 400,000 and over two million
people are affected worldwide with an expected increase in
the number of cases in future (Weinshenker 1996; Mayr
et al. 2003). The disease appears to be more common in
northern hemisphere and there is some genetic susceptibility
as well in individuals of Scandinavian or northern European
ancestry (Williams et al. 1995; Compston and Coles 2008).
The etiology although unknown presumably involves inter-
action between genetic, environmental, and other factors
triggering an aberrant autoimmune attack resulting in
damage to myelin and axons (Bruck and Stadelmann 2005).
The course of MS can be variable with a significant propor-
tion of patients experiencing some progression following the
initial relapsing remitting phase leading to significant dis-
ability (Weinshenker et al. 1989; Lublin and Reingold 1996).
Much progress has been made in the past two decades in
treating MS with the advent of effective immunomodulatory
therapies which can potentially slow down the progression
and alter the disease course.
Etiology
The etiology of MS remains unknown; however, it is
believed to be caused by immune dysregulation triggered
by genetic and environmental factors (Ascherio and
Munger 2007a,b). Although MS is not an inherited
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disease, there is a strong genetic component to its etiology
as evidenced by clustering of MS cases within families.
The risk of MS among first-degree relatives of MS
patients is 10–50 times higher than the general population
(absolute risk 2–5%); the concordance rate in monzygotic
twins is about one-third (Weinshenker 1996; Kantarci
2008). Linkage analysis studies have revealed several gene
loci as risk factors, with the major histocompatibility
complex (MHC) HLA DR15/DQ6 allele being the strong-
est one (Barcellos et al. 2003; Sawcer et al. 2011). More
recently, alleles of interleukin-2 receptor alpha gene
(IL2RA) and interleukin-7 receptor alpha gene (IL7RA)
have also been identified as inheritable risk factors (Hafler
et al. 2007; Sawcer et al. 2011). However, most of the
genetic factors underlying susceptibility still remain to be
defined. Furthermore, genetic susceptibility does not fully
explain the changes in MS risk that occur with migration
suggesting a likely role for environmental factors.
Among environmental factors, Epstein-Barr virus
(EBV) infection and vitamin D deficiency have been
extensively studied and strongly linked to MS risk (Asche-
rio and Munger 2007a,b) MS is prevalent in geographic
areas farther away from the equator (Simpson et al.
2011). Low vitamin D levels from reduced sun exposure
may be a factor contributing to increased susceptibility to
MS in these regions (Ascherio and Munger 2007b; Corre-
ale et al. 2009; Ascherio et al. 2010). Studies have sug-
gested that higher levels of vitamin D have a possible
protective role in certain susceptible patient populations
(Munger et al. 2004, 2006). The risk of developing MS is
approximately 15-fold higher among individuals with a
history of EBV infection in childhood and about 30-fold
higher among those infected with EBV in adolescence or
later in life (Ascherio 2013). However, the difference in
the risk of MS among migrants from high to low MS
prevalence areas suggests that other infectious or nonin-
fectious factors in addition to EBV may be involved
(Ascherio and Munger 2007a,b). The “hygiene hypothe-
sis,” supported by many epidemiological observations,
suggests that improved sanitation and reduced childhood
infections in developed countries may account for the
increased rates of autoimmune diseases (T-helper 1 medi-
ated) and allergy (T-helper 2 mediated) (Conradi et al.
2011). However, this hypothesis does not explain the
higher MS prevalence in rural compared to urban areas
(with expected improved sanitation) reported in some
studies (Sotgiu et al. 2003).
Cigarette smoking has also been proposed at a potential
environmental risk factor with several studies reporting
an association between smoking and MS risk and disease
activity (Wingerchuk 2012). The odds ratio for develop-
ing MS is approximately 1.5 for smokers compared with
nonsmokers (Wingerchuk 2012; Fragoso 2014). As with
other risk factors, smoking appears to influence the MS
susceptibility in conjunction with the genetic and other
environmental factors.
There is no specific diet associated with increased risk
of MS. The role of dietary factors appears to be complex
and related to the influence of multiple dietary compo-
nents including vitamin A and D, salt, omega-3-unsatu-
rated fatty acid, and polyphenol on immune regulation.
Some recent reports have suggested that salt modulates
the differentiation of human and mouse Th17 cells
(Kleinewietfeld et al. 2013; Wu et al. 2013). A more
aggressive course of experimental autoimmune encephalo-
myelitis (EAE) was observed in mice fed a high sodium
diet. In a small observational study, higher sodium intake
was associated with increased clinical and radiological dis-
ease activity in patients with MS (Farez et al. 2015).
The potential risk factors for MS are listed in Table 1.
Immunopathogenes
The pathogenesis of MS involves immune attack against
CNS antigens mediated through activated CD4+ myelin-
reactive T cells with a possible contribution by B cells.
Much of our understanding of immunopathogenesis of
MS is derived from the study of experimental autoim-
mune encephalomyelitis (EAE), an animal model of CNS
inflammatory demyelination that can be induced by
peripheral immunization with myelin protein compo-
nents. EAE shares many of the histologic features of MS
including active demyelination, oligodendrocyte and axo-
nal loss, all of which are presumably mediated by myelin
specific T cells (Yong 2004; Gold et al. 2006). The immu-
nopathogenesis of MS is thought to involve a breach of
self-tolerance toward myelin and other CNS antigens
resulting in persistent peripheral activation of autoreactive
T cells (Hafler et al. 2005; Selter and Hemmer 2013). In a
genetically susceptible individual, this loss of self-tolerance
may be triggered by an environmental antigen, presum-
ably an infectious agent such as a virus. The infection
could cause bystander activation of T cells or result in
Table 1. Potential risk factors for multiple sclerosis.
Female gender
Caucasian race
Genetic
HLA DR15/DQ6, IL2RA and IL7RA alleles
Infections
Epstein–Barr virus (EBV) infection
Temperate climate
Low vitamin D level
Lack of sunlight exposure
Cigarette smoking
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release of autoantigens due to cellular damage, which can
then lead to activation of T cells by cross reactivity
between an endogenous protein (e.g., myelin basic pro-
tein) and the pathogenic exogenous protein (viral or bac-
terial antigen), a process known as molecular mimicry
(Fujinami and Oldstone 1985; Wucherpfennig and
Strominger 1995; Aichele et al. 1996; Gran et al. 1999;
O’Connor et al. 2001).
As depicted in Figure 1, once activated in the periph-
ery, myelin-reactive T cells are able to migrate across the
blood–brain barrier (BBB). The transmigration process
involves interaction between very late antigen-4 (VLA-4)
present on T lymphocytes and the vascular cell adhesion
molecule-1 (VCAM-1) expressed on capillary endothelial
cells; this process is facilitated by expression and upregu-
lation of various adhesion molecules, chemokines, and
matrix metalloproteinases (MMPs) (Yong 2004; Gold and
Wolinsky 2011). After entering the CNS, the autoreactive
peripherally activated T cells can be reactivated upon
encountering the autoantigenic peptides within the brain
parenchyma in the context of MHC class II molecules
expressed by local antigen presenting cells (dendritic cells,
macrophages, and B cells) triggering an inflammatory cas-
cade leading to release of cytokines and chemokines,
recruitment of additional inflammatory cells including T
cells, monocytes, and B cells and persistent activation of
microglia and macrophages resulting in myelin damage
(Hemmer et al. 2002; Frohman et al. 2006; Inglese 2006).
The local inflammation and demyelination results in
exposure of sequestered myelin autoantigens providing an
additional target for self-reactive T cells, a phenomenon
called “epitope spreading” (Miller et al. 1997). Activation
of resident CNS glial cells (such as microglia) results in
persistent inflammation even in absence of further infil-
tration of exogenous inflammatory cells (O’Connor et al.
2001). The evidence based on animal studies suggests that
CD4+ T-helper 1 (TH1) cells which release proinflamma-
tory cytokines such as interferon-gamma, interleukin-2
(IL-2), and tumor necrosis factor-a (TNF-a) are the key
players in mediating inflammation in MS with some role
for the novel CD4+ T-helper-17 (TH17) cell subset which
secretes IL-17 (O’Connor et al. 2001; Selter and Hemmer
2013). The CD4+ T-helper 2 (TH2) cells, which secret in-
terleukins 4, 5, and 10 are believed to have a counter reg-
ulatory role limiting the TH1-cell-mediated injury
(Tzartos et al. 2008). The TH1/TH2 paradigm is more
apparent in EAE; in MS, indirect evidence exists for a
predominant role of Th1 cells based on the success of
therapies that shift the cytokine profile away from Th1
toward Th2. CD8+ T cells are believed to be involved as
well and can induce axonal pathology by direct injury to
MHC I/antigen expressing cells such as neurons and oli-
godendrocytes (Batoulis et al. 2010). The contribution of
B cells to MS pathogenesis (possibly through autoanti-
body secretion and antigen presentation to T cells) has
recently been recognized and is supported by observed
pathologic heterogeneity of MS lesions, the presence of
meningeal inflammation and B-cell follicle-like structures
adjacent to subpial cortical lesions, and the success of
B-cell-based immunotherapies (O’Connor et al. 2001;
Batoulis et al. 2010; Naismith et al. 2010).
Although demyelination is the hallmark of MS pathol-
ogy, early axonal injury and axonal loss also occur and
may drive disability progression (Trapp et al. 1998). The
exact mechanism(s) of both myelin and axonal injury are
not completely understood, but are likely to include both
direct injury to myelin and oligodendrocytes, and axons
by CD4+ and CD8+ T lymphocytes, activated microglia/
macrophages, and/or antibody and complement as well as
the indirect effects of proinflammatory cytokines such as
IL-1beta, TNF-a, nitric oxide, and MMPs (Lucchinetti
et al. 2000; Hemmer et al. 2002; Gold and Wolinsky
Figure 1. Immunopathogenic mechanisms
in MS and proposed targets of different
disease modifying therapies.
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2011). Meningeal inflammatory infiltrates reported in
association with subpial cortical lesions may contribute to
cortical inflammation and disability in some cases (Ho-
well et al. 2011; Lucchinetti et al. 2011).
Pathology
The MS plaques or lesions are focal areas of demyelina-
tion associated with variable inflammation and axonal
loss that predominantly affect the white matter of the
brain, spinal cord, and optic nerves but can also involve
the cerebral cortex including subpial regions (Sobel and
Moore 2008; Popescu and Lucchinetti 2012). The inflam-
matory infiltrates associated with plaques consist of acti-
vated T cells (predominantly CD8+ with variable presence
of CD4+ cells), activated macrophages/microglia, plasma
cells, and B cells (Hauser et al. 1986; O’Connor et al.
2001). MS plaques can be further classified histologically
as active, chronic, and remyelinated. Active lesions are
common in relapsing remitting MS and are characterized
by myelin degradation (with relative axonal preservation),
macrophage infiltration, reactive astrocytes, and perivas-
cular and parenchymal inflammation (Bruck et al. 1995;
Frischer et al. 2009). Chronic or inactive plaques are
more often seen in patients with progressive disease and
are associated with more extensive demyelination, often
with marked axonal depletion, loss of oligodendrocytes,
and relative absence of active inflammation (Prineas et al.
2001; Sobel and Moore 2008; Popescu and Lucchinetti
2012). Remyelinated plaques are seen within or more
often at the margins of active plaques and contain thinly
myelinated axons and often increased numbers of oligo-
dendrocyte precursor cells (Bruck et al. 1995; Popescu
and Lucchinetti 2012). “Shadow plaques” are lesions that
show more diffuse (but still incomplete) remyelination
and are seen in patients with relapsing and progressive
disease (Barkhof et al. 2003). The presence of cortical
demyelination and axonal loss has been increasingly rec-
ognized in early MS (Trapp et al. 1998; Cifelli et al.
2002). Lucchinetti and colleagues have described four dis-
tinct immmopathological patterns (pattern I with macro-
phage and T-cell predominance, II with additional
immunoglobulin and complement deposition, III with
apoptotic oligodendrocyte loss, and the rare type IV pat-
tern with nonapoptotic death of oligodendrocytes) in
active MS lesions, suggesting that there may be pathologi-
cal heterogeneity among MS patients (Lucchinetti et al.
2000). However, the observed pathologic heterogeneity
may not be exclusive to a subset of MS patients and is
probably related to the stage of disease in a given patient
(Barnett and Prineas 2004). Cortical involvement can
occur in MS and may reflect either the presence of corti-
cal demyelination or actual neuronal loss. Within the
cortex, three distinct lesion types have been described
based on the location of the plaques: subpial, intracorti-
cal, and leukocortical (Bogdan et al. 2013). Cortical
lesions seen in early MS are usually highly inflammatory
and correlate with cognitive impairment (Geurts and
Barkhof 2008; Lucchinetti et al. 2011).
Clinical Presentation and Diagnosis
The clinical symptoms and signs of MS are variable and
may result from involvement of sensory, motor, visual,
and brainstem pathways. The majority of patients with
MS initially present with relapsing remitting episodes of
new or recurrent neurological symptoms. The first clinical
event in these patients, termed clinically isolated syn-
drome (CIS), can be optic neuritis, incomplete myelitis,
or brainstem syndrome (Miller et al. 2005). The presence
of classic demyelination lesions on baseline brain or
spinal cord MRI is the most important predictor of hav-
ing a second relapse in CIS patients (Filippi et al. 1994).
The presence of cerebrospinal fluid (CSF) abnormalities
(positive oligoclonal bands) may have additional prognos-
tic value in patients with CIS and positive brain MRI
(Miller et al. 2005; Awad et al. 2010). A variable propor-
tion of patients with relapsing remitting MS (25–40%)
develop secondary progressive disease over time with pro-
gressive accumulation of disability with infrequent or no
relapses (Lublin and Reingold 1996). Primary progressive
MS (seen in approximately 10–15% patients) is defined
by progressive accumulation of disability from the onset
with no or minor relapses and typically presents with a
progressive myelopathy with an older age of onset and
involving a higher proportion of men (Miller and Leary
2007). Both primary and secondary progressive MS share
some clinical and imaging features and are now consid-
ered to be part of the progressive disease spectrum
(Lublin and Reingold 1996; Ingle et al. 2005; Lublin et al.
2014). The progressive relapsing form of MS with wors-
ening disability from onset and clear acute relapses with
or without full recovery is now considered to be progres-
sive disease with disease activity (Lublin et al. 2014).
There is no single diagnostic test for MS and the diagno-
sis is usually based on the clinical presentation, supported
by neuroimaging and in some cases by CSF analysis (to
look for inflammatory markers oligoclonal bands and/or
elevated IgG index) and evoked potential studies (to look
for clinically silent lesion in visual, brainstem, or spinal
cord pathways). CSF inflammatory markers are present in
up to 85% patients with MS (Link and Huang 2006); IgG
index is less sensitive and specific than oligoclonal bands
Awad et al. 2010). There have been several proposed diag-
nostic criteria incorporating the clinical and ancillary data,
the most commonly used one is the McDonald criteria
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initially proposed in 2001 and revised in 2005 and most
recently in 2011 (Polman et al. 2011). The basic concept
behind these criteria is demonstration of dissemination in
time (DIT) and space using the clinical and/or MRI data.
A detailed discussion of McDonald criteria is beyond the
scope of this review; in summary, the definitive diagnosis
of MS requires ≥2 attacks or objective clinical evidence of
≥ 2 lesions or objective clinical evidence of 1 lesion with
historical evidence of a prior attack. With one clinical
attack, DIT can be demonstrated by presence of asymp-
tomatic gadolinium-enhancing and nonenhancing lesions
at any time or by presence of new lesions on a follow-up
scan obtained anytime after the initial symptom onset or
the simultaneous (see Table 2). Dissemination in space
(DIS) in a patient with two clinical attacks but objective
evidence of one lesion can be demonstrated by using the
MRI criteria detailed in Table 3. The criteria for primary
progressive MS include 1 year of disease progression plus
two of the following criteria: a. evidence of DIS in brain, b.
DIS in spinal cord (≥ 2 T2 lesions in the cord), c. positive
CSF oligoclonal bands and/or elevated IgG index.
In patients presenting with typical relapsing remitting
symptoms and classic demyelination lesions (e.g., shown
in Fig. 2) on neuroimaging meeting the radiological
criteria, the differential diagnosis is limited and often no
further diagnostic testing is indicated in these cases.
The differential diagnosis in other cases depends on the
clinical presentation and is outlined in Table 4.
Atypical presentation or variants of MS
There are some less common clinical variants of MS which
present with atypical clinical and radiological features, these
include tumefactive MS, Balo’s concentric sclerosis, and
Marburg disease. The radiological hallmark of tumefactive
MS is a large solitary >2 cm lesion associated with mass
effect, edema and/or ring enhancement (hence the name
tumefactive). The clinical symptoms depend on the size
and location of the lesion and often include aphasia, agno-
sia, seizures and visual field defects, not typically seen in
CIS or RRMS patients (Lucchinetti et al. 2008). Marburg’s
disease and Balo’s concentric sclerosis are characterized by
a rapidly evolving fulminant clinical course and poor prog-
nosis. The Marburg variant has the distinct radiological fea-
ture of large tumor-like multifocal demyelinating lesions in
deep white matter; the pathological changes are similar to
those of classicMS but may appear more destructive and
have more inflammatory infiltrates (Karussis 2014). The
pathological changes seen in Balo’s concentric sclerosis are
quite unique and consist of alternating bands of normally
Table 2. McDonald MRI criteria for demonstration of DIT (Polman
et al. 2011).
DIT Can be Demonstrated by
1. A new T2 and/or gadolinium-enhancing lesion(s) on follow-up MRI,
with reference to a baseline scan, irrespective of the timing of the
baseline MRI
2. Simultaneous presence of asymptomatic gadolinium-enhancing and
nonenhancing lesions at any time
MRI, magnetic resonance imaging; DIT, lesion dissemination in time.
Based on Montalban et al. 2010.
Adapted from Polman et al. (2011).
Table 3. McDonald MRI criteria for demonstration of DIS (Polman
et al. 2011).
DIS can be demonstrated by ≥ 1 T2 lesions1 in at least 2 of the 4
area of the CNS
Periventricular
Juxtacortical
Infratentorial
Spinal cord2
MRI, magnetic resonance imaging; DIS, lesion dissemination in space;
CNS, central nervous system.
Based on Swanton et al. 2006, 2007.
Adapted from Polman et al. (2011).
1Gadolinium enhancement of lesions is not required for DIS.
2If a subject has a brainstem or spinal cord syndrome, the symptom-
atic lesions are excluded from the Criteria and do not contribute to
lesion count.
Figure 2. Brain MRI axial fluid attenuated inversion recovery (FLAIR)
image shows the characteristic periventricular areas of increased
signal intensity (arrows) that are oriented perpendicular to and often
contiguous with the lateral ventricles.
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myelinated or remyelinated, and demyelinated white mat-
ter; this pattern has been described as resembling hypoxia-
induced injury (Stadelmann et al. 2005). The MRI may
show alternating isointense and hypointense concentric
rings with partial enhancement on T1-weighted images
(Zettl et al. 2012; Karussis 2014).
Therapeutic Options
The management of MS includes treatment with immuno-
modulatory agents that help alter the course of the disease,
symptomatic management focusing on relieving specific
symptoms such as fatigue, spasticity, bladder dysfunction,
and pain (not discussed in this review). Corticosteroids
(methylprednisolone) and adrenocorticotropic hormone
(ACTH) have anti-inflammatory and immunomodulatory
effects and are typically used to treat acute relapse to hasten
the recovery (Berkovich 2013). The immunomodulatory
therapies (IMT) used in long-term disease modification are
discussed in the next section.
Immunomodulatory Therapies
The most significant progress in the treatment of MS in the
last two decades has been the development of IMT. Since
the introduction of first immunomodulating medication,
interferon beta-1b in 1993, several other medications with
different mechanism of action (figure 1), mode and fre-
quency of administration have become available. Currently,
there are 12 medications approved for treatment of MS,
including six self-injectable, three infusion based, and three
oral medications as listed in Table 5.
The mechanism of action of IMT used for treatment of
MS is broad suppression of the immune response medi-
ated by autoreactive lymphocytes; most of these are effec-
tive in relapsing remitting MS where inflammatory
demyelination is the primary process (Weinstock-Gutt-
man et al. 1995; Rudick et al. 1997; Damal et al. 2013).
The goal of these therapies is to reduce the frequency of
relapses and number of MRI lesions (new, enlarging and/
or enhancing T2 lesions), and slow the disability progres-
sion. Most of these agents have shown good efficacy in
patients with relapsing remitting MS and clinically iso-
lated syndrome, however, their benefit in patients with
progressive disease has been questionable (Filippini et al.
2013). The mechanism of action and side-effect profile of
different IMTs are briefly discussed here with the excep-
tion of alemtuzumab, the latest medication to be
approved for treatment of MS.
Beta-Interferon
Interferons (IFNs) are endogenous proteins that are
involved in immune response against viral and bacterial
agents and were the first class of disease modifying agents
developed for treatment of MS. The beta-interferons
(IFN-b) have multiple actions including stabilizing the
BBB thereby limiting the entry of T cells into the CNS,
modulating T- and B-cell function, and altering the
expression of cytokines (Yong et al. 1998; Weber et al.
1999; Dhib-Jalbut 2002). Several different preparations of
IFN- b are available and are listed in Table 5. Both IFN-
b1a and IFN-b1b have shown similar efficacy and are
considered first line agents for treating patients with
relapsing MS and CIS (Rudick et al. 1997). Although two
different trials with IFN- b1b showed conflicting results
in secondary progressive MS, it may be indicated in
patients with continued relapses (Kappos et al. 2004).
The side effects of beta-interferon include flu-like symp-
toms, depression, liver enzyme elevation, thyroid abnor-
malities, leukopenia or anemia, and injection site
reactions (Rudick et al. 1997).
Glatiramer Acetate
Glatiramer acetate (GA) or Copolymer 1 is a synthetic
complex of four amino acids that mimics myelin basic
protein (MBP), one of the autoantigens targeted by the T
cells. Due to its structural similarity to MBP, GA blocks
the formation of myelin reactive T cells and induces
GA-specific regulatory T-cell expression and Th2 anti-
inflammatory cytokine production (bystander suppres-
sion) (Wolinsky 1995; Rudick et al. 1997; Gran et al.
2000; Dhib-Jalbut 2002; Ruggieri et al. 2007). The clinical
efficacy of GA in terms of reducing relapse rate and MRI
Table 4. Differential diagnosis of multiple sclerosis
Optic neuritis/neuropathy
Inflammatory, neuromyelitis optica (NMO) spectrum disorder,
genetic, ischemic
Myelitis/myelopathy—
Inflammatory demyelination—idiopathic, postviral, postvaccinialNMO
spectrum disorder, Autoimmune–systemic lupus erythematosus,
antiphospholipid antibody syndrome, other systemic autoimmune
disorders
Infectious (Lyme disease, HIV, viral, others)
Ischemic/vascular
Others–compressive, nutritional
Brainstem syndrome
Stroke, tumor, vasculitis (lupus, Sj€ogren’s syndrome, Behcet’s
disease)
Cerebral white matter lesions
Small vessel disease (Leukoaraiosis)
Migraine
Primary CNS vasculitis
Sarcoidosis
CADASIL (Cerebral Autosomal Dominant Arteriopathy with
Subcortical Infarcts and Leukoencephalopathy)
Brain and Behavior, doi: 10.1002/brb3.362 (6 of 13) ª 2015 The Authors. Brain and Behavior published by Wiley Periodicals, Inc.
An update on Multiple Sclerosis N. Garg & T. W. Smith
lesions is similar to IFN-b, however, GA has somewhat
limited effect on disability progression (Rudick et al.
1997; La Mantia et al. 2010). The side effect profile of GA
is, however, more favorable and includes local injection
site reactions, post injection reaction (flushing, chest
tightness, palpitation, and dyspnea within minutes of
injection with spontaneous resolution) and rare lipoatro-
phy with prolonged use.
Natalizumab
Natalizumab is a humanized monoclonal antibody that
binds a4b1-integrin on lymphocytes blocking their
interaction with VCAM-1 on endothelial cells thereby
preventing the transmigration of lymphocytes across the
BBB (Ransohoff 2007). Its superior efficacy has been
demonstrated in two phase 3 studies with a robust effect
on relapse rate reduction and disability progression
(Miller et al. 2003; Polman et al. 2006). The major safety
concern with natalizumab is progressive multifocal leu-
koencephalopathy (PML), a serious potentially fatal
opportunistic brain infection caused by reactivation of JC
virus (Yousry et al. 2006). As of December 2014, 514
cases of PML have been reported worldwide with post-
marketing use of natalizumab (TYSABRI [natalizumab]
2014). The overall risk of PML in MS patients with
Table 5. Approved therapies for multiple sclerosis
Medication Dose Route Frequency Major side effects
First-line therapies
Beta-interferon-1b
(Betaseron, Bayer HealthCare
Pharmaceuticals Inc.,
Whippany, NJ)
250 µg SC Every other day Flu-like symptoms, injection site reactions, liver
enzyme elevation, thyroid abnormalities,
leukopenia or anemia, and depression
Beta-interferon-1a
(Avonex, Biogen Idec,
Cambridge, MA )
30 µg IM Once a week
Peginterferon beta-1a
(Plegridy, Biogen Idec,
Cambridge, MA)
125 µg SC Every 14 days
Beta-interferon-1a (Rebif,
EMD Serono, Inc. Rockland, MA )
44 µg SC Three times weekly
Beta-interferon-1b (Extavia,
Bayer HealthCare Pharmaceuticals
Inc., Montville, NJ)
250 µg SC Every other day
Glatiramer acetate (Copaxone,
TEVA Neuroscience, Inc.,
Overland Park, KS )
20 mg SC Daily Local injection site reactions, postinjection
reaction (flushing, chest tightness, palpitation,
and dyspnea) and rare lipoatrophy with
prolonged use
40 mg SC Three times weekly
Second line therapies
Natalizumab (Tysabri,
Biogen Idec, Cambridge, MA)
300 mg IV Every 4 weeks Hepatotoxicity, infusion reactions, progressive
multifocal encephalopathy (PML)
Mitoxantrone (Novantrone,
EMD Serono, Inc. Rockland, MA)
Weight-based dose IV Every 3 months Cardiotoxicity, secondary leukemia
Fingolimod (Gilenya, Novartis
Pharma Stein AG Stein, Switzerland)
0.5 mg Oral Once daily First dose bradycardia, atrioventricular block,
herpes virus infection, macular edema,
elevated blood pressure, rare risk of PML
Teriflunomide (Aubagio, Genzyme
Corporation, Cambridge, MA)
7 and 14 mg Oral Once daily Hair loss, headache, diarrhea, hepatotoxicity,
teratogenicity, increased risk of infections due
to lymphopenia
Dimethyl fumarate (Tecfidera,
Biogen Idec., Cambridge, MA )
240 mg Oral Twice daily GI effects-nausea, diarrhea, abdominal pain,
flushing, pruritus, liver enzyme elevation,
lymphopenia, rare cases of PML
Alemtuzumab (Lemtrada,
Genzyme Corporation,
Cambridge, MA )
12 mg or 24 mg IV Per day (5 days in year
1, 3 days in year 2)
Serious infusion reactions, secondary
autoimmune diseases-thryoiditis,
thrombocytopenia, anti-glomerual basement
membrane disease, increased risk of
malignancies—thyroid cancer, melanoma,
lymphoproliferative disorders
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natalizumab use is 3.78 per 1000 with a much higher risk
(13/1000) among patients with prolonged duration of
therapy (≥24 months), history of prior immunosuppres-
sive therapy, and positive JC virus antibody status
(Bloomgren et al. 2012; Information M, 2014). Due to
the risk of PML, natalizumab now has a more limited use
as a second line drug in patients with breakthrough dis-
ease or intolerable side effects with first line therapies.
Mitoxantrone
Mitoxantrone is a synthetic anthracendione antineoplastic
agent; its immunomodulatory effects include suppression
of T and B lymphocytes and macrophage proliferation.
Mitoxantrone is indicated for reducing disability and
relapse frequency in patients with worsening relapsing
remitting and secondary-progressive MS, however, its use
has been limited due to risk of dose-related cardiotoxicity
and treatment-related leukemia (Fox 2006).
Oral Therapies
Three new oral medications have recently become avail-
able for treatment of relapsing MS: fingolimod, terifluno-
mide, and dimethylfumarate. The efficacy of these
medications has been established in several phase 3 stud-
ies with comparable or somewhat better effect (compared
to some injectable therapies) on relapse rate reduction,
MRI lesions, and disability progression.
Fingolimod is a sphingosine-1-phosphate receptor
(S1P1) modulator and was the first oral drug approved
for treatment of MS. By binding to S1P1 receptor on the
T cells, it prevents emigration of activated T cells from
lymph nodes thereby limiting their entry into the CNS
(Chiba et al. 1998; Pelletier and Hafler 2012). The poten-
tial side effects of fingolimod include first dose bradycar-
dia, atrioventricular block, herpes virus infection, macular
edema, elevated blood pressure, and a reported cases of
PML (Cohen et al. 2010; Kappos et al. 2010; Samson
2013; Calic et al. 2015).
There have been a total of three reported cases of PML
associated with use of fingolimod, two of these occurred
in context of prior immunosuppressive therapy, the third
most recent case, however, was reported in a patient with
no prior immunosuppressive therapy after more than
4 years of fingolimod use (Calic et al. 2015; Case of PML
reported in patient treated with Gilenya, 2015). A single
case of sudden suspected cardiac death within 24 h of
taking first dose of fingolimod was reported in December
2011 (Lindsey et al. 2012). Even though a direct associa-
tion with the medication could not be established, the US
Food and Drug Administration and European regulatory
agency released new monitoring guidelines for first dose
monitoring and the drug is now contraindicated in
patients with history of cardiac disease or stroke and
patients on antiarrhythmic medications.
Teriflunomide is an active metabolite of leflunomide (a
drug used to treat rheumatoid arthritis) and is an inhibi-
Inial clinical presentaon: 
RRMS or CIS
Diagnosis conﬁrmed by 
McDonald criteria
Iniate ﬁrst line IMT with 
IFN-β or GARRMS
No
Further diagnosc workup to 
rule out MS mimics
Subopmal response
Intolerable side eﬀects
Poor compliance
CIS
Oﬀer IMT (IFN-β or GA)
or
follow-up MRI (3-6 months)
6-12 month f/u
Switch among ﬁrst line or to 
second line agents
Treatment algorithm for mulple sclerosis
Figure 3. Treatment approach to patients
with RRMS and CIS.
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tor of enzyme dihyrdro-orotate dehydrogenase (DHODH)
which interferes with denovo synthesis of pyrimidine in
rapidly dividing cells (Oh and O’Connor 2013). Its anti-
inflammatory effect in MS is believed to be mediated by
reducing the activity of proliferating T and B lympho-
cytes. Teriflunomide does not affect the resting or slowly
dividing hematopoietic cells which use the alternate
DHODH independent “salvage pathway” for pyrimidine
synthesis, therefore, preserving the basic homeostatic
functions of these cells and immune surveillance (Oh and
O’Connor 2013). Leflunomide is converted almost
entirely into teriflunomide after absorption and taken at
the recommended doses, both drugs result in similar
plasma concentration of teriflunomide (AUBAGIO (teri-
flunomide) Prescibing information. 2014). The short-term
side effects of teriflunomide are relatively mild and include
hair loss, headache, diarrhea, and elevated liver enzymes
(O’Connor et al. 2011). Reduction in lymphocyte and
neutrophil counts, elevated blood pressure, and a single
case of latent tuberculosis are some of the other side
effects reported (O’Connor et al. 2011; Confavreux et al.
2014). The potential teratogenecity of teriflunomide
remains a major concern although several pregnancies
reported during its clinical trial did not have any adverse
outcome. Nevertheless, strict contraception is recom-
mended to avoid pregnancy and a rapid elimination pro-
cess is undertaken in women who become pregnant while
taking teriflunomide as the drug can remain in the systems
for 8 months to 2 years (Confavreux et al. 2014).
Dimethylfumarate (DMF) or BG12 is the latest oral
therapy to be approved for treatment of MS. Related to
fumaric acid ester which has been used for treatment of
psoriasis in Germany since 1990s; BG12 is as an enteric
coated formulation of DMF with improved GI tolerabil-
ity. It is hydrolyzed to monomethyl fumarate soon after
oral absorption. The mechanism of action of DMF
involves inhibition of proinflammatory pathways via
activation of nuclear factor erythroid 2-related factor 2
(Nrf-2) antioxidant response pathway (Linker et al.
2011). The most common side effect with DMF include
nausea, diarrhea, abdominal pain which can be mini-
mized by taking the medication with food and flushing
which can be reduced by aspirin (Gold et al. 2012; Fox
et al. 2014). Lymphopenia may occur although no
increased infection risk was observed in phase 3 studies
(Fox et al. 2012; Gold et al. 2012). There have been a few
cases of PML reported with use of fumaric acid ester for-
mulations in patients with psoriasis with pronounced pro-
longed lymphopenia being the major risk factor (Ermis
et al. 2013; van Oosten et al. 2013; Sweetser et al. 2013).
There has been a recent report of a fatal case of PML
in a patient with multiple sclerosis treated with
dimethyl fumarate (FDA Drug Safety Communication,
2014). In response to these cases of PML, JC virus
antibody testing and close monitoring for lymphopenia
has been suggested in patients initiating DMF therapy
to improve surveillance.
The oral medications are currently considered second
line due to a greater risk of serious side effects making
their safety profile less favorable in patients with early
and mild disease. The main safety concern with oral med-
ications is the potential for prolonged immunosuppres-
sion increasing the risk of serious infections and also
malignancies due to altered immune surveillance. A sim-
plified treatment algorithm for patients with RRMS and
CIS is outlined in Figure 3.
In summary, there has been significant progress in the
field of MS with better understanding of immunopatho-
genesis, wider availability and use of MRI, and availability
of disease modifying therapies. There are currently a wide
range of therapeutic options to treat MS including the
recently approved oral drugs. However, balancing the
safety and efficacy of these drugs remains a challenge due
to serious side effects associated with more effective thera-
pies. Given the heterogeneity of MS, personalized treat-
ment by recognizing specific genetic markers in individual
patients has been proposed. Also, there is an urgent need
for novel therapeutic agents that can prevent or minimize
the neuronal and/or axonal degeneration occurring in
patients with progressive MS.
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